Posts

Argenx Acquires Forte Biosciences for $2.2 Billion to Add Phase 2‑Stage Vitiligo and Celiac Drug FB102 to Its Immunology Pipeline

on

Huyabio scores with Opdivo combo in 'milestone' skin cancer trial

on

Merck’s IBD Drug from $10.8B Prometheus Deal Claims First Phase 3 Win

on

ADA 2026: Zealand and Roche pitch amylin agonist petrelintide as best‑in‑class obesity monotherapy

on

Roche's incretin GLP‑1/GIP shot shows promise in mid‑stage trial for type 1 diabetes

on

Biogen advances Alzheimer’s tau program despite midphase miss

on

Amgen Abandons Cancer and Sjögren's Candidates Due to Weak Phase 2 Data

on

Oruka Therapeutics Announces Strong Phase 2a Results for ORKA-001 in Plaque Psoriasis, Outperforming Skyrizi

on

Sanofi's Bispecific Scores Double Respiratory Phase 2 Wins but Flunks Eczema Study

on

PepGen's PGN-EDODM1 Phase 2 Trial Shows Mixed Mid-Stage Results with One Patient Outlier

on

Biogen Announces Positive Phase 2 Results for Litifilimab in Cutaneous Lupus Erythematosus from AMETHYST Study

on

"A Bit of a Surprise": Kardigan's Tonlamarsen Shows No Blood Pressure Benefit from Repeat Dosing in Phase 2 Trial

on

Medicus Pharma Business Update Call Highlights 80% ORR in Phase 2 SkinJect Study and AI-Enabled Drug Development

on

Apogee Therapeutics' Phase 2 Data Positions Zumilokibart (APG777) as Convenient Alternative to Dupixent and Ebglyss in Eczema Treatment

on

Pfizer's Atirmociclib Delivers Positive Phase 2 Results in Metastatic Breast Cancer

on

Structure Therapeutics Reports Strong Phase 2 ACCESS II Data for Oral GLP-1 Aleniglipron with 16% Weight Loss

on

Ascletis Reports Positive Phase 2 Data for Quarterly-Dosing GLP-1 ASC30 in Obesity

on

Celldex Reports Strong Retreatment Results With Barzolvolimab In Cold Urticaria and Symptomatic Dermographism

on

AstraZeneca's Oral GLP-1 Obesity Pill Succeeds in Phase 2 Trials Amid Broader Portfolio Expansion

on

Boehringer Ingelheim Advances Apecotrep to Phase 3 for Rare Kidney Disease FSGS Despite Mixed Mid-Stage Data

on